Over 422 million people suffer from diabetes. By 2040 this number is expected to rise to 642 million.*
These figures equate to approximately 8.5% of the world adult population, and trends show that this number is rising, as lifestyles grow ever more sedentary and obesity and inactivity continue to cause problems for health services across the globe.
Living with insulin-treated diabetes can be challenging. Complications arising from an imbalance of insulin in the body can mean illness and discomfort for patients, and costs of millions of pounds for health services.
Sweden-based company Brighter was launched in order to provide services and solutions that facilitate self-care and self-monitoring for patients to help them manage their diabetes better. Of course, giving patients the tools they need to manage their diabetes accurately and reliably doesn’t mean that health professionals are no longer monitoring patients. In fact, Brighter makes it easier for doctors and nurses to monitor their patients as data is collected more accurately and consistently. Information about a patient’s insulin levels and general health is stored and delivered through a cloud-based platform, and patients can choose to share real-time data with their caregivers for ongoing monitoring purposes, or even for access in an emergency.
Brighter has developed Actiste – a connected device that gathers personal health data from diabetes patients and shares it with their caregivers, enabling patients to better manage their condition and caregivers to monitor and personalise their treatment more accurately. Patients and caregivers can track sugar levels and insulin dosages using a dedicated app, and the device administers the correct levels of insulin required when needed, whilst keeping track of exactly how much insulin a patient has injected.
Unlike anything else on the market today, Actiste facilitates measurement of glucose levels, insulin injection, and automatic logging and timing of all activity within a single unit, making life better for people with diabetes.
You can find out more about the Actiste device in this video.
Living with a condition like diabetes can sometimes make it harder to experience life to the full. Going on holiday abroad, for example, can be a challenge for people with diabetes. Globally connected eUICC technology within the Actiste device means that patients can travel, reassured that they can keep their diabetes accurately under control, and that Actiste can help them to stay in touch with their caregiver back home.
Brighter’s vision is that patients get the best possible user experience and from a connectivity point of view, this means that cellular connectivity works without intervention from the user. That means zero touch connectivity without the need for pairing to Wifi or Bluetooth. It means no bill shock due to unintended roaming. Data security (GDPR) is also a critical dimension for Actiste users and data localisation is a key element in addressing that. Actiste is an eUICC device which means that network connectivity can be managed remotely and automatically, leveraging a combination of global roaming and localised network connections. Arkessa is extremely proud to provide eUICC and cellular services for Actiste, and look forward to see it fulfilling its world-changing potential.
*World Health Organisation Global Report on Diabetes, 2014